Locust Walk acquisition Q3 profit beat expectations, while revenue beat expectations. – Locust Walk Acquisition Company (NASDAQ: ) Q3 Report Beats Analyst Estimates Revenue remains at the same level as forecasted. According to reports on Monday

Locust Walk Acquisition’s earnings per share (EPS) was $-0.120 on revenue of $0.00. The analyst consensus compiled by for the upcoming forecast was previously seen at $-0.125 per share based on earnings of $0.00.

Apart from the Locust Walk acquisition, there are other companies too. Markets report this month’s earnings in the healthcare sector of the NASDAQ Stock Exchange

Eli Lilly previously estimated Q3 earnings at $0.1 per share on revenue of $9.5B, and $-0.2 on revenue of $8.97B.

Meanwhile, UnitedHealth’s most recently reported performance beat analyst forecasts. Q3 earnings were $6.56 per share on revenue of $92.4B, beating analyst estimates for 2020. expects earnings per share to be around $6.33 based on revenue of $91.42B.

Follow the latest developments in company profits with the Earnings Calendar

Leave a Reply

Your email address will not be published. Required fields are marked *